40

nanotimes

Companies Facts

types, different experimental setups, and different outcome measures. The first human clinical trials of the vaccine are expected to start in 2011. The origi- nal work on VXM01 was conducted at The Scripps Research Institute and the project was in-licensed by VAXIMM from Merck KGaA in 2008. http://www.vaximm.com

V

eeco Instruments Inc. (NASDAQ: VECO) announced that Thomas Gutierrez has been

appointed to its Board of Directors. Mr. Gutierrez, age 62, currently serves as President, Chief Executive Officer and Director of GT Solar International, Inc. (NASDAQ: SOLR), a global provider of polysilicon production technology, and sapphire and silicon crystalline growth systems and materials for the solar, LED and other specialty markets.

Furthermore, Veeco announced its financial results for the fourth quarter and full-year ended December

31, 2010. John R. Peeler, Veeco’s Chief Executive Officer, commented, “The fourth quarter of 2010 was the best in our history, and we are extremely proud of our performance. Revenues were $300 mil- lion, gross margin was 51% and net income was $97 million. Veeco’s revenues grew 8% sequentially and 152% from the fourth quarter of last year. Both Vee- co segments delivered excellent performance: LED & Solar revenues were up 6% sequentially to a record $258 million, and Data Storage revenues were up 21% to $42 million, our best quarter since 2008.

Full year 2010 results were also at record levels, with revenue of $933 million and net income of $261 million. These results were achieved through a com- bination of world-class products, a focus on high- growth market opportunities, operational excellence,

our flexible manufacturing strategy, and a deep commitment to satisfying our global customers.”

Veeco’s first quarter 2011 revenue is currently forecasted to be between $215 and $265 million. Earnings per share are currently forecasted to be between $0.94 to $1.31 on a GAAP basis and $1.02 to $1.39 on a non-GAAP basis. Please refer to the attached financial table for more details.

“With starting backlog of $555 million, and antici- pating strong first half 2011 bookings, we currently forecast that Veeco’s 2011 revenues will be greater than $1 billion, resulting in non-GAAP earnings per share of greater than $5.00,” continued Mr. Peeler. http://www.veeco.com

lithography systems with a vacuum compatible air- bearing based positioning system overcoming the li- mitations of roller bearings for future performance re- quirements. The new platform is designed to support both Vistec‘s Variable Shaped Beam (VSB) writers as well as the Multi Shaped Beam (MSB) lithography system currently under development.

V

The combination of the new highly sophisticated platform with advanced variable shaped beam elec- tron optics enables Vistec to address mask writing as well as electron-beam direct write application demands for future technology nodes according to the ITRS roadmap. In addition, a multitude of special application needs, e.g. in the micro- and nano-optics area will be met.

istec Electron Beam GmbH announced that the company is ready to provide its electron-beam

11-01 :: December 2010 / January 2011